System: You are an AI assistant for producing a structured representation of given unstructured text. Follow instructions
precisely and to the letter; refrain from inventing content that is not in the text.

User: Below, you will be given a text on participation criteria from a clinical trial on cancer drugs, marked by PARTICIPATION CRITERIA: """.
Summarize the information on the tumor malignancy (including TNM stages), and on any prior treatment received in the text marked by """.

-------------------------------
    
PARTICIPATION CRITERIA: """
Inclusion Criteria:

Age ≥ 18 years.
Measurable disease according to RECIST 1.1 within 28 days prior to registration.
Documented pathologic diagnosis of RCC. All subtypes eligible including but not limited to clear cell, papillary, chromophobe, collecting duct carcinoma, medullary carcinoma, and unclassified categories. Sarcomatoid and rhabdoid differentiation are allowed.
Patients with clear cell histology must have demonstrated: 1) Progression on at least one prior anti -angiogenic agent unless intolerable; AND 2) progression on at least one agent that blocks the PD-1 pathway unless felt by the treating physician to be contraindicated (examples include but are not limited to: patients with autoimmune disease or patients requiring systemic steroids greater than 10 mg/day prednisone or its equivalent) or if they have been discontinued due to toxicity. Prior rapalogues are allowed.
Patients with non-clear cell histology must have received at least one prior anti-cancer therapy. Prior rapalogues are allowed.
Left ventricular ejection fraction (LVEF) ³ lower limit of normal (LLN) as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO).
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Must have adequate organ and bone marrow function.